AI English summary of an SEC filing — figures as filed

The company said Dietmar Berger, M.D., Ph.D., will succeed Merdad V. Parsey, M.D., Ph.D., as Chief Medical Officer, effective December 12, 2024 and January 2, 2025.

8-K/ADeparture or Appointment of Directors or Certain Officers (amended)Amended filingFiled Dec 13, 2024Period of report Jul 17, 2024Summary published (UTC) Oct 25, 2026

Key points

AI summary

The company said Dietmar Berger, M.D., Ph.D., will succeed Merdad V. Parsey, M.D., Ph.D., as Chief Medical Officer, effective December 12, 2024 and January 2, 2025.
Gilead said Dr. Parsey agreed to remain with the company as a Senior Advisor through Q1 2025, at which point his employment will be terminated without cause.
Berger will take responsibility for Gilead's virology, oncology and inflammation portfolio and oversee the global Development and Medical Affairs organizations, the company said. He will also become a member of the senior leadership team.
The company said Dr. Berger brings more than 25 years of drug development experience. He was most recently Chief Medical Officer and Global Head of Development at Sanofi, and previously held senior development roles at Atara, Genentech, Bayer and Amgen.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Chief Medical Officer Transition Announced

The company said Dietmar Berger, M.D., Ph.D., will succeed Merdad V. Parsey, M.D., Ph.D., as Chief Medical Officer, effective December 12, 2024 and January 2, 2025.

Source · Based on the filing body and exhibits

Parsey to Remain as Senior Advisor, Then Employment to End

Gilead said Dr. Parsey agreed to remain with the company as a Senior Advisor through Q1 2025, at which point his employment will be terminated without cause.

Source · Based on the filing body and exhibits

Berger's Responsibilities

Berger will take responsibility for Gilead's virology, oncology and inflammation portfolio and oversee the global Development and Medical Affairs organizations, the company said. He will also become a member of the senior leadership team.

Source · Based on the filing body and exhibits

Berger's Career Background

The company said Dr. Berger brings more than 25 years of drug development experience. He was most recently Chief Medical Officer and Global Head of Development at Sanofi, and previously held senior development roles at Atara, Genentech, Bayer and Amgen.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.